Kremen1 Antibody

What is Kremen1 and why is it significant in current research?

Kremen1 (Kringle-containing protein marking the eye and the nose, also known as KRM1) is a type I transmembrane protein containing extracellular kringle, WSC, and CUB domains, with an intracellular region lacking conserved motifs . It functions primarily as:

• A high-affinity Dickkopf homolog 1 (DKK1) receptor that modulates canonical Wnt/β-catenin signaling

• An alternative receptor for SARS-CoV-2 entry, functioning independently of ACE2 in certain cell types

• A cellular receptor for multiple enteroviruses causing hand, foot, and mouth disease (HFMD)

• A dependence receptor that triggers apoptosis unless bound to its ligand DKK1

Its significance has expanded dramatically in recent years from Wnt signaling regulation to viral pathogenesis, making Kremen1 antibodies crucial tools for investigating these diverse biological processes.

What are the optimal conditions for using Kremen1 antibodies in Western blot applications?

For optimal Western blot detection of Kremen1:

Note that observed band size may vary slightly between species and due to post-translational modifications. Always include appropriate positive controls to validate antibody specificity.

How should Kremen1 antibodies be stored and handled to maintain optimal activity?

For maximum stability and activity retention of Kremen1 antibodies:

• Store lyophilized antibodies at -20 to -70°C for up to 12 months from receipt date

• After reconstitution, store at 2-8°C for up to 1 month under sterile conditions

• For longer storage after reconstitution, aliquot and store at -20 to -70°C for up to 6 months

• Avoid repeated freeze-thaw cycles by preparing appropriate aliquots

• For liquid antibody formulations containing preservatives (e.g., sodium azide and glycerol), storage at -20°C is generally sufficient without aliquoting

• When working with antibodies, maintain cold chain and limit exposure to room temperature

How does Kremen1 function as an alternative receptor for SARS-CoV-2, and what experimental approaches are best for studying this interaction?

Kremen1 functions as an ACE2-independent alternative receptor for SARS-CoV-2:

Key Findings:

• The CUB domain of Kremen1 is critical for binding the SARS-CoV-2 spike (S) protein

• Kremen1-dependent virus entry operates distinctly from ACE2-dependent pathways

• Kremen1 contributes to viral tropism in certain cell types, particularly relevant for understanding infection in ACE2-low tissues

Recommended Experimental Approaches:

• Domain-specific binding assays: Test S protein binding using Kremen1 constructs with domain deletions or chimeric human/mouse domains

• Knockdown experiments: Use shRNA targeting Kremen1 in cell lines to measure impact on viral entry

• In vivo models: Transduction of mice with Kremen1-expressing adenovirus allows assessment of its role in authentic SARS-CoV-2 infection

• Cell line selection: HTB-182 cells show strong Kremen1-dependent, ACE2-independent viral entry, making them valuable for studying this pathway

• Blocking antibodies: Neutralizing antibodies targeting the Kremen1 CUB domain can be used to inhibit viral entry

These approaches should ideally be combined with positive controls (ACE2-expressing cells) and negative controls (mock-transduced cells) for comprehensive analysis.

What is the significance of Kremen1 homodimerization in apoptotic signaling, and how can this be experimentally investigated?

Kremen1 homodimerization is crucial for its function as a dependence receptor:

Key Mechanisms:

• Kremen1 triggers apoptosis when not bound to its ligand DKK1

• Apoptotic signaling requires homodimerization of Kremen1 receptors

• DKK1 binding inhibits Kremen1 multimerization, thereby preventing cell death

• Kremen2, which lacks intrinsic apoptotic activity, can bind and compete with Kremen1, functioning as a potent inhibitor of Kremen1-induced cell death

Recommended Experimental Approaches:

• Forced dimerization assays: Using chemical inducers of dimerization to force Kremen1 multimerization and measure apoptotic outcomes

• Competition assays: Co-expressing Kremen1 and Kremen2 at varying ratios to assess inhibition of apoptotic signaling

• Survival analysis correlation: Analysis of patient data shows that the association between low KREMEN2 expression and better survival increases with KREMEN1 expression levels

• Protein-protein interaction studies: Co-immunoprecipitation or proximity ligation assays to detect Kremen1-Kremen1 or Kremen1-Kremen2 interactions

These approaches provide insights into how Kremen1 homodimerization functions as a regulatory mechanism for cell death signaling in cancer and normal tissues.

How is the completely conserved VP2 residue K140 involved in Kremen1-dependent enterovirus infections?

The VP2 capsid protein residue K140 (designated K2140) plays a critical role in Kremen1-dependent enterovirus infections:

Key Findings:

• K2140 is completely conserved across all strains of Kremen1-dependent enteroviruses (CVA2, CVA3, CVA4, CVA5, CVA6, CVA10, and CVA12)

• This residue is indispensable for receptor recognition, cell attachment, and infection by these viruses

• K2140 contributes significantly to viral pathogenicity in vivo

• Residue D90 of Kremen1 engages with K2140 and is crucial for Kremen1-mediated enterovirus infections

• The identification of K2140 conservation allowed prediction and experimental confirmation that CVA8 also utilizes Kremen1 as its receptor

Experimental Approaches:

• Mutational analysis: Generate K2140 mutants in viral capsid proteins to assess impact on binding and infection

• Structural studies: Investigate the molecular interaction between K2140 and Kremen1 D90 residue

• Infection assays: Compare wild-type and K2140-mutant viruses for cell attachment and infection efficiency

• In vivo pathogenicity models: Assess the contribution of K2140 to viral virulence in animal models

• Receptor-blocking strategies: Develop peptides or antibodies targeting the K2140-D90 interaction as potential therapeutic interventions

This research provides valuable insights for developing broad-spectrum therapies against HFMD-causing enteroviruses that utilize Kremen1 as a receptor.

What controls should be included when validating Kremen1 antibody specificity in immunohistochemistry applications?

For rigorous validation of Kremen1 antibody specificity in immunohistochemistry:

Essential Controls:

• Positive tissue controls: Human colon cancer tissue and normal human colon have been validated for Kremen1 detection

• Negative primary antibody control: Omit primary antibody but include secondary antibody and detection reagents to assess background staining

• Antigen blocking: Pre-incubate antibody with recombinant Kremen1 protein before staining to demonstrate specific binding

• Cross-reactivity assessment: Test against Kremen2-expressing tissues (human Kremen1 antibodies show <5% cross-reactivity with Kremen2)

• Optimized protocol elements:

  • Recommended antibody concentration: 5-15 μg/mL

  • Incubation conditions: Overnight at 4°C

  • Antigen retrieval: Use Antigen Retrieval Reagent-Basic (e.g., Catalog # CTS013)

  • Detection system: Anti-Goat HRP-DAB Cell & Tissue Staining Kit (for goat primary antibodies)

  • Counterstain: Hematoxylin provides good contrast with DAB staining

Proper validation using these controls ensures reliable and reproducible immunohistochemical detection of Kremen1 in research applications.

How can researchers effectively distinguish between Kremen1 and Kremen2 in functional studies?

Distinguishing between Kremen1 and Kremen2 requires careful experimental design:

Specific Approaches:

• Antibody selection: Use antibodies validated for minimal cross-reactivity (<5% between human Kremen1 antibodies and Kremen2)

• Functional differences:

  • Kremen1 exhibits apoptotic activity when not bound to DKK1, while Kremen2 lacks this intrinsic apoptotic function

  • Kremen2 can inhibit Kremen1-induced cell death through competitive binding

• Expression analysis:

  • qPCR with isoform-specific primers targeting unique regions

  • RNAscope in situ hybridization for tissue-specific expression patterns

• Knockdown/Knockout strategies:

  • siRNA/shRNA with validated specificity for each paralog

  • CRISPR/Cas9 targeting unique exons of each gene

• Binding studies:

  • Kremen1 shows higher affinity for certain virus capsid proteins compared to Kremen2

  • Different binding affinities for DKK proteins can be used for discrimination

Understanding the distinct and overlapping functions of these paralogs is crucial, particularly in cancer research where KREMEN2 is upregulated in most cancers and may counteract Kremen1's tumor suppressor activity .

What methodological approaches are optimal for studying Kremen1's dual roles in Wnt signaling and viral pathogenesis?

To investigate Kremen1's diverse functions, researchers should consider:

Wnt Signaling Investigation:

• TOPFlash/FOPFlash reporter assays to measure β-catenin-dependent transcriptional activity in response to:

  • DKK1 treatment with/without Kremen1 expression

  • Kremen1 domain mutations affecting DKK1 binding

• Co-immunoprecipitation studies to analyze:

  • Kremen1-DKK1-LRP5/6 ternary complex formation

  • Internalization dynamics using surface biotinylation

Viral Pathogenesis Investigation:

• Domain mapping to identify regions important for:

  • SARS-CoV-2 spike protein binding (CUB domain)

  • Enterovirus capsid protein interaction (focusing on D90 residue)

• Receptor competition assays using:

  • Soluble Kremen1 ectodomains to block viral entry

  • Antibodies targeting specific Kremen1 domains

Integrated Approaches:

• Domain-specific mutations to create Kremen1 variants that:

  • Selectively affect viral binding but preserve Wnt signaling

  • Disrupt DKK1 interaction but maintain viral receptor functions

• Cell-type specific analysis to understand:

  • Differential expression in tissues susceptible to viral infection

  • Correlation between Wnt pathway activity and viral susceptibility

• In vivo models with tissue-specific Kremen1 deletion to assess:

  • Developmental phenotypes (Wnt-related)

  • Viral susceptibility and pathogenesis

These complementary approaches can elucidate how Kremen1's multiple functions are coordinated and potentially exploited for therapeutic interventions.

What are the common issues encountered when using Kremen1 antibodies in Western blot, and how can they be resolved?

For reproducible results, prepare samples under reducing conditions and use appropriate buffer systems (e.g., Immunoblot Buffer Group 7 has been validated for Kremen1 detection) .

How can researchers optimize immunohistochemistry protocols for detecting Kremen1 in different tissue types?

Optimization strategies for Kremen1 immunohistochemistry across tissue types:

Sample Preparation:

• Fixation: 10% neutral buffered formalin fixation for 24-48 hours

• Sectioning: 4-5 μm sections on positively charged slides

• Paraffin removal: Complete deparaffinization and rehydration

Protocol Optimization by Tissue Type:

• Colon/Colon cancer tissue (validated positive controls) :

  • Antigen retrieval: Basic pH retrieval solution (e.g., Catalog # CTS013)

  • Antibody concentration: 15 μg/mL

  • Incubation: Overnight at 4°C

• Liver tissue (high endogenous Kremen1 expression) :

  • Additional peroxidase quenching may be needed

  • Consider shorter antibody incubation (4-6 hours)

  • Lower antibody concentration may be sufficient (5-10 μg/mL)

• Low-expressing tissues:

  • Extended antigen retrieval time

  • Higher antibody concentration (up to 15 μg/mL)

  • Signal amplification systems

General Optimization Parameters:

• Antigen retrieval: Test both heat-induced epitope retrieval (HIER) and enzymatic methods

• Antibody titration: Test concentration range (5-15 μg/mL) for each tissue type

• Detection systems: Compare chromogenic (DAB) vs. fluorescent detection for sensitivity

• Counterstaining: Adjust hematoxylin timing based on tissue type

Include both positive controls (colon cancer tissue) and negative controls (primary antibody omission) with each staining run to ensure protocol reliability.

How can CRISPR/Cas9 gene editing be utilized to study Kremen1 function in viral infection models?

CRISPR/Cas9 approaches offer powerful tools for investigating Kremen1 biology in viral infections:

Experimental Strategies:

• Complete Kremen1 knockout:

  • Guide RNA design targeting early exons or critical functional domains

  • Validation in cell lines with known Kremen1-dependent viral susceptibility (e.g., HTB-182 for SARS-CoV-2)

  • Phenotypic assessment: viral entry, replication, cytopathic effects

• Domain-specific editing:

  • Precise mutations in the CUB domain (critical for SARS-CoV-2 binding)

  • Targeted modification of D90 residue (important for enterovirus binding)

  • HDR-mediated knock-in of tagged versions for live imaging

• Promoter modification:

  • CRISPRa/CRISPRi for modulating endogenous Kremen1 expression levels

  • Analysis of dosage effects on viral susceptibility

• In vivo applications:

  • Tissue-specific Kremen1 deletion/modification in mouse models

  • Viral challenge studies comparing wild-type and Kremen1-modified animals

Functional Readouts:

• Viral entry/infection assays with reporter viruses

• Competitive infection assays between wild-type and Kremen1-edited cells

• Transcriptomic profiling to identify downstream pathways

• Interaction proteomics to define virus-induced Kremen1 complexes

These approaches will provide mechanistic insights into how Kremen1 functions in viral pathogenesis and potentially identify novel therapeutic targets.

What are the emerging roles of Kremen1 in disease pathogenesis beyond its established functions?

Recent research has revealed expanding roles for Kremen1 in multiple disease contexts:

1. Infectious Diseases:

• Functions as an alternative receptor for SARS-CoV-2, contributing to COVID-19 pathogenesis

• Serves as the primary receptor for multiple enteroviruses causing hand, foot, and mouth disease (HFMD)

• The conserved interaction between viral VP2 K140 residue and Kremen1 D90 represents a potential broad-spectrum target

2. Cancer Biology:

• Acts as a tumor suppressor through dependence receptor function, triggering apoptosis in ligand-poor environments

• KREMEN1 expression correlates with improved survival outcomes

• KREMEN2 is upregulated in multiple cancers and may counteract KREMEN1's tumor-suppressive effects

• Altered Wnt signaling through Kremen1 dysregulation contributes to colorectal carcinogenesis

3. Developmental Disorders:

• Variations and mutations in KREMEN1 have been associated with ectodermal dysplasia

• Essential for proper development of nervous system, limbs, and liver through Wnt pathway modulation

4. Potential Therapeutic Applications:

• Targeting the Kremen1-virus interaction interface for broad antiviral development

• Modulating Kremen1/Kremen2 ratio in cancers to promote apoptosis of tumor cells

• Utilizing soluble Kremen1 ectodomains to modify Wnt signaling in regenerative medicine

Future research should focus on integrating these diverse functions to understand how Kremen1 coordinates cellular responses across different physiological and pathological contexts.

What approaches can be used to study the interplay between Kremen1 and Kremen2 in normal development and disease?

To investigate the complex relationship between these paralogous receptors:

Comparative Expression Analysis:

• Single-cell RNA sequencing to map cell-type specific expression patterns

• Spatial transcriptomics to visualize expression domains in developing tissues

• Temporal expression profiling during embryogenesis and disease progression

Functional Redundancy vs. Antagonism:

• Single and double knockout models:

  • Compare phenotypes of Kremen1-/-, Kremen2-/-, and Kremen1-/-;Kremen2-/- models

  • Tissue-specific conditional knockouts to avoid developmental lethality

  • Rescue experiments with each paralog

• Protein-protein interaction studies:

  • Investigate formation of Kremen1-Kremen2 heterodimers

  • Determine how heterodimers affect:

    • DKK binding and Wnt pathway regulation

    • Apoptotic signaling

    • Viral receptor function

• Ratio manipulation experiments:

  • Overexpress one paralog while knocking down the other

  • Analyze effects on cell survival, Wnt signaling, and viral susceptibility

  • Test if altering Kremen1:Kremen2 ratio affects cancer cell survival

Disease-Relevant Models:

• Cancer cell lines with varying Kremen1:Kremen2 ratios to study survival outcomes

• Viral infection models to determine if Kremen2 competes with Kremen1 for virus binding

• Developmental models focusing on tissues where both paralogs are expressed